Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cazzaniga, G
Right arrow Articles by Biondi, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cazzaniga, G
Right arrow Articles by Biondi, A
Haematologica, Vol 90, Issue 3, 382-390
Copyright © 2005 by Ferrata Storti Foundation

Journal Article

Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology

G Cazzaniga and A Biondi

Centro Ricerca M. Tettamanti, Clinica Pediatrica Universita Milano-Bicocca, Ospedale S.Gerardo, Monza, Italy. gianni.cazzaniga@hsgerardo.org

The use of minimal residual disease (MRD) measurement as a surrogate marker of molecular response to treatment can potentially improve the evaluation of treatment response and enable estimates of the residual leukemic cell burden during clinical remission, thereby improving the selection of therapeutic strategies and, possibly, long-term clinical outcome. The most specific and sensitive methods for MRD monitoring currently available are polymerase chain reaction amplification of rearranged immunoglobulin and antigen-receptor genes, and flow cytometric detection of aberrant immunophenotypes. Several retrospective studies have demonstrated the strong association between MRD and risk of relapse in childhood acute lymphoid leukemia (ALL), irrespective of the methodology used. The promising results on the predictivity of MRD evaluation at the end of induction treatment has challenged the need for a new definition of remission. There is now urgent need to incorporate MRD data into clinical studies, properly designed to address treatment questions, in order to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL. However, several critical issues must be resolved before MRD determinations can be routinely considered in clinical decision making.


This article has been cited by other articles:


Home page
 JCOHome page
L. Mussolin, M. Pillon, V. Conter, M. Piglione, L. Lo Nigro, P. Pierani, C. Micalizzi, S. Buffardi, G. Basso, L. Zanesco, et al.
Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of Childhood
J. Clin. Oncol., November 20, 2007; 25(33): 5254 - 5261.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Choi, M. J. Henderson, E. Kwan, A. H. Beesley, R. Sutton, A. Y. Bahar, J. Giles, N. C. Venn, L. D. Pozza, D. L. Baker, et al.
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone
Blood, July 15, 2007; 110(2): 632 - 639.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. Bagg
Immunoglobulin and T-Cell Receptor Gene Rearrangements: Minding Your B's and T's in Assessing Lineage and Clonality in Neoplastic Lymphoproliferative Disorders
J. Mol. Diagn., September 1, 2006; 8(4): 426 - 429.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.